OTUD6B and pulmonary arterial hypertension: To test whether the reduction of Otud6b inhibits PAH development, we targeted Otud6b (siOtud6b, GGGAATGAAGAACGCCGTT) and non-targeted control (siNC) modified anti-siRNA oligonucleotides by trachea infusion for 3 weeks.